{"id":108560,"date":"2017-07-27T20:59:11","date_gmt":"2017-07-28T00:59:11","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=108560"},"modified":"2017-07-27T20:59:11","modified_gmt":"2017-07-28T00:59:11","slug":"pioneering-cancer-drug-could-benefit-more-patients","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2017\/07\/27\/pioneering-cancer-drug-could-benefit-more-patients\/","title":{"rendered":"Pioneering cancer drug could benefit more patients"},"content":{"rendered":"
\"Intermediate<\/a>
Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left – diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. (Photo By Nephron, CC BY-SA 3.0)<\/a><\/figcaption><\/figure>\n

LONDON, July 28 — A new drug developed at the University of Sheffield could become available to patients diagnosed with a wide range of cancers, the university said on Thursday.<\/p>\n

Lynparza, the world’s first and leading PARP inhibitor, is currently available for the treatment of some women with advanced BRCA2-related ovarian cancer.<\/p>\n

In 2005, Professor Thomas Helleday and his team of researchers at the University of Sheffield demonstrated how PARP inhibitors could be used as a tailored treatment for patients with BRCA2 mutations, which are seen in both hereditary ovarian and breast cancer. PARP inhibitors work by blocking the cancer cell’s ability to repair damage.<\/p>\n

The discovery was patent protected and licensed to pharmaceutical company AstraZeneca, which continued the development process and undertook successful clinical trials. Now AstraZeneca and Merck & Co., Inc., have announced a global strategic oncology collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.<\/p>\n

“We welcome the announcement that AstraZeneca and Merck are working together to make this groundbreaking treatment available to more patients,” said Professor Dave Petley, Vice-President for Research and Innovation at the University of Sheffield.<\/p>\n

The drug will be developed as monotherapy and in combination with other potential medicines, further increasing the number of treatment options available for patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

LONDON, July 28 — A new drug developed at the University of Sheffield could become available to patients diagnosed with …<\/p>\n","protected":false},"author":33,"featured_media":108565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[3741,4408,380,6804,19908,19907],"class_list":["post-108560","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-astrazeneca","tag-cancer","tag-drug","tag-inc","tag-merck-co","tag-university-of-sheffield","mauthors-xinhua","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/108560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=108560"}],"version-history":[{"count":0,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/108560\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/108565"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=108560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=108560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=108560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}